178 related articles for article (PubMed ID: 27965472)
1. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Even AJ; Hamming-Vrieze O; van Elmpt W; Winnepenninckx VJ; Heukelom J; Tesselaar ME; Vogel WV; Hoeben A; Zegers CM; Vugts DJ; van Dongen GA; Bartelink H; Mottaghy FM; Hoebers F; Lambin P
Oncotarget; 2017 Jan; 8(3):3870-3880. PubMed ID: 27965472
[TBL] [Abstract][Full Text] [Related]
2. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
3. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
4. Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley TA; Da Pieve C; Martins CD; Ciobota DM; Allott L; Oyen WJG; Harrington KJ; Smith G; Kramer-Marek G
J Nucl Med; 2019 Mar; 60(3):353-361. PubMed ID: 30213849
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
van Loon J; Even AJG; Aerts HJWL; Öllers M; Hoebers F; van Elmpt W; Dubois L; Dingemans AC; Lalisang RI; Kempers P; Brans B; Winnepenninckx V; Speel EJ; Thunnissen E; Smits KM; Boellaard R; Vugts DJ; De Ruysscher D; Lambin P
Radiother Oncol; 2017 Feb; 122(2):267-273. PubMed ID: 28012793
[TBL] [Abstract][Full Text] [Related]
6. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
7. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
[TBL] [Abstract][Full Text] [Related]
8.
Benedetto R; Massicano AVF; Crenshaw BK; Oliveira R; Reis RM; Araújo EB; Lapi SE
Cancer Biother Radiopharm; 2019 Jun; 34(5):288-296. PubMed ID: 30865493
[No Abstract] [Full Text] [Related]
9. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
10. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
11. Validation of simplified uptake measures against dynamic Patlak K
Wijngaarden JE; Huisman MC; Jauw YWS; van Dongen GAMS; Greuter HNJM; Schuit RC; Cleveland M; Gootjes EC; Vugts DJ; Menke-van der Houven van Oordt CW; Boellaard R
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1897-1905. PubMed ID: 36820891
[TBL] [Abstract][Full Text] [Related]
12. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
13. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
14. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
van Dijk LK; Boerman OC; Kaanders JH; Bussink J
Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
[TBL] [Abstract][Full Text] [Related]
17. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
19. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
20. Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.
Van den Wyngaert T; Helsen N; Carp L; Hakim S; Martens MJ; Hutsebaut I; Debruyne PR; Maes ALM; van Dinther J; Van Laer CG; Hoekstra OS; De Bree R; Meersschout SAE; Lenssen O; Vermorken JB; Van den Weyngaert D; Stroobants S;
J Clin Oncol; 2017 Oct; 35(30):3458-3464. PubMed ID: 28854069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
